Vycor Medical Posts Operating Profit in Q1 2026 as International Sales Drive Revenue Growth
Vycor Medical reported a 5% revenue increase to $458,540 for Q1 2026, achieving an operating profit of $45,808 compared to a loss last year, driven by international expansion and supported by new clinical studies on its ViewSite Brain Access System.
Vycor Medical, Inc. (OTCQB: VYCO) announced financial results for the three months ended March 31, 2026, reporting a return to operating profitability driven by international sales growth and cost management. The company, which operates through its Vycor Medical and NovaVision divisions, posted revenue of $458,540, a 5% increase from $436,378 in the same period of 2025.
The Vycor Medical division, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons, generated $440,441 in revenue, up 5% from $418,520 a year earlier. The company attributed most of the growth to international markets, a key strategic focus. Gross profit for the division rose to $359,040, maintaining a margin of 82%. The NovaVision division, still in development, contributed $18,099 in revenue, with a gross margin of 89%.
On a GAAP basis, Vycor reported an operating profit of $45,808, compared to an operating loss of $(12,806) in Q1 2025. Non-GAAP operating profit, which excludes non-cash depreciation and stock-based compensation, reached $59,788, up from $20,388 in the prior-year period. Non-GAAP cash operating expenses decreased to $315,365 from $338,146, reflecting disciplined cost control. Despite the operational improvement, the company reported a net loss available to common stockholders of $(142,077) due to preferred stock dividends, compared to a $(200,748) loss in Q1 2025.
Vycor also highlighted the publication of two new peer-reviewed studies on VBAS during the first quarter, bringing the total published clinical papers to over 50. One case study focused on a complex pediatric tumor, emphasizing the effectiveness of integrating neuro-navigation systems with VBAS as "a paramount strategy for the surgical resection" of such lesions. A second retrospective study of 23 tumor resection patients compared outcomes using VBAS versus traditional blade retractors, finding significantly fewer new neurological deficits at follow-up in the tubular retractor group, implying safer tumor resection with VBAS.
The company’s ViewSite Brain Access System is FDA-cleared and used in over 350 hospitals in the U.S. and internationally, protected by 49 issued and 8 pending patents. The NovaVision division offers Visual Restoration Therapy (VRT), the only commercialized FDA-cleared therapy for vision rehabilitation after neurological brain damage, along with the NeuroEyeCoach program supported by a 296-patient study. Vycor noted that NovaVision therapies require significant development to realize their market potential.
The results underscore Vycor’s progress in expanding its global footprint and achieving operational profitability, while continuing to build clinical evidence for its products. The company’s focus on international growth and cost management appears to be yielding tangible financial improvements, positioning it for potential future expansion.